(CercleFinance.com) – The stock ends up following the analysis of UBS, which announced on Friday that it had resumed coverage of the Icade stock with a buy recommendation, against a ‘neutral’ opinion previously, and a price target raised from 76 to 80 euros.
In a study released in the morning, the financial intermediary argues that the potential presented by the health activities of the real estate group more than compensates for the difficulties encountered by its office buildings.
“We believe that Icade is better insulated from disruptions in the commercial real estate sector than its current stock market prices suggest,” writes the analyst in the note.
According to UBS, this context could offer the real estate operator the necessary time to position itself on new opportunities.
‘With 45% of cash coming from healthcare – where structural trends are favorable – and optionality on offices and business parks, we perceive limited downside risk with total return potential that could reach 29% at over the next 12 months,’ says UBS.